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Dendritic cells (DC) are crucial cells of the immune system, and bridged the essential connection between innate 
and adaptive immunity. They reside in the periphery as sentinels where they take up antigens. Upon activation, 
they migrate to lymphoid organs and present there the processed antigens to T cells, thereby activating them and 
eliciting a potent immune response. Dendritic cells are bone marrow-derived cells, still big controversies exist 
about their in vivo development. In vitro, DC can be generated from multiple precursor cells, among them 
lymphoid and myeloid committed progenitors. Although it remains unknown how DC are generated in vivo, 
studying the functions of in vitro generated DC results in fundamental knowledge of the DC biology with promising 
applications for future medicine. Therefore, in this review, we present current protocols for the generation of DC 
from precursors in vitro. We will do this for the mouse system, where most research occurs and for the human 
system, where research concentrates on implementing DC biology in disease treatments. Cellular & Molecular 
Immunology. 2005;2(1):28-35. 
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Introduction 
 
Dendritic cells (DCs) were initially described by Ralph 
Steinman in 1973 as dendritic appearing cells in lymphoid 
organs (1). Subsequently, DC have been described in more 
and more tissues. Nowadays, it is thought that most organs 
possess their own DC populations. DC belong to the 
mononuclear phagocyte system (MPS), in contrast to the 
polymorphonuclear neutrophils. Both of them show avid 
phagocytosis. Yet different from the other members of the 
MPS, the macrophages, phagocytosis is not DC’s main task. 
Once DC have been activated, they will start to migrate to 
lymph nodes. During this migration, DC will process uptaken 
antigens and put them onto the cell surface complexes with 
MHC class I or class II molecules. They will also upregulate 
the expression of other cell surface molecules, so called 
costimulatory molecules, which will later be used to interact 
with T cells. The process of upregulating the expression of 
antigen-MHC class I or class II complexes and costimulatory 
molecules is called maturation. Maturation happens during 
migration and is essential for DC to perform their main 
function later: to activate T cells. 
Once DC have arrived in draining lymph nodes, and push 
T cells into one of the direction followed by their interaction: 
polarize them toward a Th1 or a Th2 response, or induce T 
regulatory cells. The factors that dictate these directions are 
not exactly known so far and are subject to ongoing 
investigations. Nevertheless, what can be said is that the way 
DC are activated and the interactions DC are having during 
their migration into lymph nodes with other cells of the 
immune system such as macrophages, NK cells, NKT cells 
and B cells are shaping the activation state of DC. According 
to this state, DC will thereafter push T cells further or less 
far. 
For T cells to get efficiently activated, they require three 
signals: (i) They need to recognize their antigen in the 
context of MHC class I (for CD8+ T cells) or MHC class II 
(for CD4+ T cells). Each T cell carries a unique T cell 
receptor and only those cells that recognize the antigens that 
the DC present will become activated. (ii) T cells need the 
costimulatory molecules that DC have upregulated during 
maturation. This is the reason why immature DC in the 
periphery cannot activate T cells efficiently. (iii) Next to 
these two signals, it has become clear during the last ten 
years that these two signals themselves are not enough to 
activate T cells and a third signal is required. This signal is 
most probably delivered in the form of soluble molecules, i.e., 
cytokines and chemokines, which are produced by DC and 
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directly affect T cells in a paracrine fashion (2). 
Due to the link function that DC perform between the 
periphery, where pathogens arise, and the lymph nodes, 
where immunity against them is induced, DC are at a key 
position of the immune system. Moreover, it has also been 
recognized recently that DC in a healthy body perform the 
crucial function to induce tolerance for the body’s own 
antigens (3). Therefore, manipulating DC seems to be a 
potent way to treat persistent infectious diseases and cancers 
by enhancing DC functions, and to treat diseases of an 
overreacting immune system, such as autoimmune diseases 
and allergies, by enhancing DC functions to induce tolerance 
(4). Yet, in order to do so, DC have to be obtained, either by 
isolating them directly from the body or by culturing them 
from isolated precursors. In the following sections, we will 
discuss protocols to culture DC from human and from mouse 
precursors. 
 
Heterogeneity of DC subsets 
 
In the last two decades, the hybridoma technology has 
delivered us a wealth of monoclonal antibodies against 
multiple molecules on the surface of diverse cells types. By 
using these antibodies for immunochemistry or flow 
cytometry stainings, different DC subsets both in humans and 
in mice have been described. Thereby, both lymphoid organs 
(thymus and bone marrow as primary lymphoid organs; 
lymph nodes, spleen and gut associated lymphoid tissues 
such as appendix, tonsils, adenoids and Peyer’s patches as 
secondary lymphoid organs) as well as non-lymphoid organs 
(blood, skin, other peripheral organs) have been investigated. 
Table 1 summarizes the current division of DC subpopula- 
tions in different organs in humans. For example, in the 
human thymus, three distinct DC subpopulations have been 
described, according to their different expression of HLA-DR 
(MHC class II), CD11c and CD13 (Figure 1A). In human 
lymph nodes, also three DC subsets are distinguished, 
whereas at least four DC subsets have been found in the 
spleen. And in human tonsils, five subpopulations have been 
identified (Figure 1B). 
The situation in mice is as complex as the one in humans 
(Table 2). Two DC subsets were found in the murine thymus, 
distinguishable from each other by their CD8α expression 
level. In the mouse spleen, four DC subsets have been 
Table 1. Phenotype of different DCs subsets in human 
 
 Phenotype of DC subsets References 
Thymus 
 
Lin- 
HLA-DRint 
CD11c+ 
CD13+ 
IL-3Rαlow 
CD45RAlow  
(Immature DC) 
Lin- 
HLA-DRint 
CD11c- 
CD13- 
IL-3Rαhigh 
CD45RAhigh 
(Plasmacytoid DC) 
Lin- 
HLA-DRhigh 
CD11c+ 
CD13+ 
IL-3Rαlow 
CD45RAlow 
(Mature DC) 
  6 
Spleen CD11c+ 
CD86- 
CD83- 
CD14- 
CD11b- 
CD11c+ 
CD86+ 
CD83+ 
CD11c+ 
CD86- 
CD80- 
CD83- 
CD14low 
CD11b+ 
HLA-DR+ 
CD11c- 
 7 
Lymph nodes CD1a+ 
CD86-/dim 
CD83-/dim 
CD1a- 
CD86+ 
CD83+ 
CD1abright 
CD86+ 
CD83+ 
  8 
Tonsils HLA-DRhi 
CD11c+ 
HLA-DRmod 
CD11c+ 
CD13+ 
HLA-DRmod 
CD11c+ 
CD13- 
HLA-DRmod 
CD11c- 
CD123+ 
(Plasmacytoid) 
HLA-DRmod 
CD11c- 
CD123- 
9 
Peyer’s patches No available     - 
Blood Lin- 
HLA-DR+ 
CD1b/c+ 
Lin- 
HLA-DR+ 
BDCA-3+ 
Lin- 
HLA-DR+ 
CD123hi 
(plasmacytoid) 
Lin- 
HLA-DR+ 
CD16+ 
Lin- 
HLA-DR+ 
CD34+ 
10 
Skin (dermis) CD11c+ 
Factor XIIIa+ 
CD1a+ 
CD14- 
CD11c+ 
Factor XIIIa+ 
CD1a- 
CD14- 
CD11c+ 
Factor XIIIa+ 
CD1a- 
CD14+ 
CD11c+ 
Langerin + 
 11 
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described: two myeloid DC subsets, one lymphoid subset, 
and the plasmacytoid DC precursor subset (Table 2). The 
classification of DC subsets myeloid and lymphoid DC has 
been proposed, when it was found that T cell precursors, 
which are lymphoid committed cells, could form thymic DC 
as well (5). The expression of markers that are normally 
expressed by lymphocytes (i.e., CD8α) was taken as a hint 
that these cells in vivo indeed stem from lymphoid committed 
cells. In the meantime, it has been recognized that myeloid 
committed cells as well as lymphoid committed cells can 
give rise to both myeloid and lymphoid DC subsets. 
Moreover, until now it is still not clear whether CD8α 
expression on DC indeed means an independent DC 
development pathway, or if it is merely a DC activation 
HLA-DR
C
D
13
R1
R2
R3
HLA-DR
C
D
11
c
R4
R5
R6
Lin
FS
C
R0
In R0
In R0
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C
D
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C
D
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Figure 1. Human DC subsets identified by flow cytometry. (A) Human thymic DC subsets. Thymic single cell suspensions are gated 
according to their Lin– (CD3, CD7, CD14, CD19 and CD56) phenotype (R0). Thereafter, three DC subpopulations can be identified according 
to their CD13 or CD11c and HLA-DR (MHC class II) expression: HLA-DRintCD11c+ CD13+ iDC (R1 and R4), HLA-DRintCD11c-CD13-
pDCp (R2 and R5) and HLA-DRhiCD11c+CD13+ mDC (R3 and R6). (B) Human tonsil DC subsets. CD11c and HLA-DR define three tonsil 
DC subsets that are HLA-DRhiCD11c+, HLA-DRmodCD11c+ (R1), and HLA-DRmodCD11c– (R2). Double negative cells are not DC. 
HLA-DRmodCD11c+ cells (R1) can be further divided into two subsets according to CD13 expression, and HLA-DRmodCD11c-cells (R2) can be 
divided into a CD123+ and a CD123- subsets according to CD123 expression. 
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marker. Langerhans cells, the DC subset of the epidermis 
(see also below), have been shown to upregulate CD8α 
expression upon maturation. Nevertheless, the terms myeloid 
and lymphoid DC subsets are still used in connection to their 
expression of myeloid vs. lymphoid markers (CD11b vs. 
CD8α) (19). Plasmacytoid DC precursors have been 
described quite a long time ago as plasmacytoid cells (thus 
cells with a large cytoplasm) in T cell areas of lymphoid 
organs. They were recognized not be classical plasma cell, 
but their true function remained unknown. As a consequence, 
they were called plasmacytoid monocytes or plasmacytoid T 
cells. Recently, it has been discovered that plasmacytoid DC 
precursors produce massive amounts of type I interferons 
(e.g. IFN-α and IFN-β) upon activation, Moreover, once 
activated, these cells develop into genuine DC that can 
potentially stimulate T cells. Therefore, they were renamed 
plasmacytoid DC precursors. About these cells, there are 
convincing hints that they may in vivo originate from 
lymphoid precursors: they show D-J recombinations in their 
heavy chain loci, express the CD3ε mRNA, and their MHC 
class II expression is regulated the same way as for B cells 
but different from other DC (20). 
Murine lymph nodes (LN) have been shown to harbor the 
same four DC subsets as the spleen does. Moreover, lymph 
nodes possess additional DC subsets: The mesenteric LN, 
which belong to the intestine-draining LN, harbors one 
additional DC subsets, whereas skin draining lymph nodes 
harbor two additional DC subsets, one derived from the 
epidermis and the other one from the dermis (see also 
below). 
In non-lymphoid organs, human blood has been shown to 
contain five different subsets of DC, whereas mice possess 
two. Another organ that is under intense investigation due to 
its easy accessibility is the skin. Skin is a vast organ, and 
except its physical barrier function, it also plays an important 
role in immunity. The skin is made up of three layers: 
epidermis, dermis and subcutaneous tissue. Both in humans 
and mice, Langerhans cells as DC of the epidermis have been 
recognized. These cells can now easily been stained with 
antibodies that recognize Langerin, a Langerhans cell-specific 
Table 2. Phenotype of different DCs subsets in mouse 
 
 Phenotype of DC subsets References
Thymus DEC-205high 
CD11blow 
CD8αhigh 
DEC-205high 
CD11blow 
CD8αlow 
    12 
Spleen MHC IIlow 
CD11c+ 
CD11b+ 
CD205- 
CD8α- 
CD4+ 
B220- 
(Myeloid) 
MHC IIlow 
CD11c+ 
CD11b+ 
CD205- 
CD8α- 
CD4- 
B220- 
(Myeloid) 
MHC IIlow 
CD11c+ 
CD11b- 
CD205+ 
CD8α+ 
B220- 
(Lymphoid) 
MHC IIlow 
CD11c+ 
CD11b- 
CD205- 
CD8α+/- 
B220+ 
Gr1+ 
(Plasmacytoid)
  12, 13, 16
Lymph nodes MHC IIlow 
CD11c+ 
CD11b+ 
CD205- 
CD8α- 
CD4+ 
B220- 
(Myeloid) 
MHC IIlow 
CD11c+ 
CD11b+ 
CD205- 
CD8α- 
CD4- 
B220- 
(Myeloid) 
MHC IIlow 
CD11c+ 
CD11b- 
CD205+ 
CD8α+ 
B220- 
(Lymphoid) 
MHC IIlow 
CD11c+ 
CD11b- 
CD205- 
CD8α+/CD4+ 
B220+ 
Gr1+ 
(Plasmacytoid)
MHC IIhigh 
CD11c+ 
CD11b+ 
CD205int 
CD8αlow 
B220- 
(Only in skin-draining 
LN and Mesenteric LN) 
MHC IIhigh 
CD11c+ 
CD11b+ 
CD205high 
CD8αint 
B220- 
(Only in skin- 
draining LN) 
13 
Peyer’s patches CD11c+ 
B220- 
CD11b+ 
CD8α- 
 (Myeloid) 
CD11c+ 
B220- 
CD11b- 
CD8α+ 
(Lymphoid) 
CD11c+ 
B220- 
CD11b- 
CD8α- 
CD11c+ 
B220+ 
CD11b- 
CD19- 
(Plasmacytoid)
  14, 18 
Blood 
 
CD11clow 
CD11b- 
CD45RAhigh 
(Plasmacytoid) 
CD11c+ 
CD11b+ 
CD45RA- 
    15 
Skin (dermis) 
 
CD11c+ 
Langerin- 
CD11c+ 
Langerin+ 
    17 
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molecule. The murine dermis consists of another dermal DC 
population. Langerhans cells that are migrating through the 
dermis can be found there as well. The human dermis has 
been shown to harbor three dermal DC subpopulations, all of 
which express the coagulation factor XIIIa (FXIIIa). DC 
subpopulations in the subcutaneous tissue have not yet been 
described so far.  
Knowledge of different DC subsets in different organs is 
essential for studying their origins and their differentiation 
pathways. Only with this knowledge, we can correlate in 
vitro generated DC with their in vivo counterparts and draw 
conclusions about the functions of in vitro generated DC that 
are used for in vivo vaccinations. 
 
In vitro generation of human DC 
 
The earliest DC precursors can be found in the bone marrow, 
where it has been shown that hematopoietic stem cells can 
give rise to DC. Sufficient numbers of hematopoietic stem 
cells can also been obtained from human umbilical cord 
blood. Additionally, blood monocytes have been shown to be 
DC precursors, and DC can be generated efficiently by 
culturing monocytes. DC populations can also be isolated 
directly from peripheral blood, lymphoid organs or peripheral 
tissues (e.g. Langerhans cells from human epidermis). In the 
following sections, we will describe the generally used 
protocols to generate human DC from precursors. 
 
Culture of myeloid DC using CD34+ hematopoietic stem cells 
isolated from human cord blood (21, 22)  
Hematopoietic stem cells (HSC) can be collected from 
umbilical cord blood through positive selection using CD34 
monoclonal Abs (mAbs) and goat anti-mouse IgG-coated 
microbeads. CD34+ HSC are then cultured in RPMI medium, 
supplemented with 10% FCS, rhGM-CSF and rhTNF-α for 5 
days. Optimal conditions are maintained by splitting these 
cultures at day 4 with medium containing fresh GM-CSF and 
TNF-α, the most efficient cell concentration used has been 
determined to be 1 to 3 × 105 cells/ml. After 5 to 6 days of 
culture, cells are separated into CD14+CD1a- or CD14-CD1a+ 
progenitors 
CD34+ myeloid
CD34+ lymphoid
rhGM-CSF+rhTNF-α
PBMo:
CD14+
CD11c+
CD1a-
PBDC:
CD14-
CD11c+
CD1a+
rhGM-CSF
rhIL-4
Blood progenitors 
rhGM-CSF
rhIL-4
rhGM-CSF
rhIL-4
TGF-β
Interstitial (dermal) DC Langerhans DC  
 
Figure 2. In vitro human DC generation. Culturing CD34+ hematopoietic stem cells with rhGM-CSF and rhTNF-α for 5 to 6 days leads to 
the generation of two subsets that are either CD1a-CD14+CD11c+ or CD1a+CD14-CD11c+. The first subset can further develop into interstitial 
DC if cultured with rhGM-CSF and rhTNF-α, or develop into Langerhans DCs if cultured with rhGM-CSF, rhTNF-α and TGF-β. The CD1a+
CD14-CD11c+ cells will develop further into Langerhans DCs when cultured with rhGM-CSF and rhTNF-α. 
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subpopulations, either of the two subpopulations can be 
cultured further on for 6 to 7 additional days in the presence 
of GM-CSF plus TNF, with a last medium refreshing step 
being performed at day 10. Routinely between day 11 and 
day 14, two DC populations can be collected suitable for 
further DC experiments (Figure 2). 
 
Culture of myeloid DC using peripheral blood mononuclear 
cells (PBMC) (23-26)  
PBMC are isolated from whole blood by Ficoll-Hypaque 
gradient centrifugation. By selecting for CD14, CD14+ and 
CD14- precursors can be obtained and subsequently cultured 
separately for 6-7 days in 10% FCS, rhGM-CSF and rhIL-4 
supplemented RPMI-medium, with or without rhTGF-β. 
Whereas a lack of rhTGF-β gives rise to typical interstitial 
(dermal) DC, the addition of rhTGF-β skews them into a 
more Langerhans cells-like phenotype. Both DC subsets 
show typical phenotypic and functional profile of immature 
DC. Up to 8 × 106 DC have been obtained from 40 ml of 
blood. Moreover, other cytokine combinations can be used to 
obtain different DC subpopulations (Figure 2). 
 
Culture of plasmacytoid DC precursors (27)  
Plasmacytoid DC precursors (pDCp) can be cultured from 
peripheral blood hematopoietic stem cells in vitro (30). 
Alternatively, they can be purified from human blood, tonsils 
or other lymphoid organs by their specific expression of 
BDCA-2 (a pDCp specific C-type lectin), BDCA-4 
(neurophilin-1) or CD123 (IL-3Rα). Whereas selecting 
pDCp with BDCA-2 mAbs has been shown to inhibit type I 
interferon production of pDCp, BDCA-4 mAbs did not have 
any effect on these cells. pDCp cannot be sustained with 
GM-CSF, but they proliferate when cultured with IL-3 and 
they can be mobilized in vivo by Flt-3L treatment. For in 
vitro culturing, in brief, tonsils are cut into small pieces and 
digested for 10-15 min with collagenase IV and 
deoxyribonuclease I, after two rounds of tissue digestion, 
cells are centrifuged over 50% Percoll for 20 min at 400 g. 
Then deplete CD3+ T cells, CD14+ monocytes, CD19+ and 
CD20+ B cells, and CD56+ NK cells, CD4+CD3-CD11c-Lin- 
cells are isolated by cell sorting, and in the end put into 
culture with IL-3 supplemented RPMI-10% FCS medium for 
3-6 days.  
There is no popular method to culture lymphoid DC in 
vitro, but claims exist that lymphoid DC can be derived from 
bone marrow and thymus (28, 29), Galy et al. identified a 
subset of progenitor cells defined by the phenotype CD34+ 
CD38+Thy-1-CD10+. When cultured under appropriate condi- 
tion, they were capable of giving rise to T, B, NK and DC but 
not to myeloid cell types. CD10 was suggested to distinguish 
myeloid and lymphoid origins. Similarly, a CD34+ Thy-1- but 
CD38dim foetal thymic precursor gave rise to T, NK and DC 
but not myeloid lineages. One important question is that this 
population can still be plasmacytoid DC, which are also 
lymphoid committed cells, so further identification need to 
be done. 
 
In vitro generation of murine DC 
 
In the mouse system it is inconvenient to isolate DC 
R4
Ly6C
C
D
31 R1
R2
R3
R5
R6
R1: erythrocytes precursors
R2: T and B precursors
R3: early blast cells
R4: myeloid blasts
R5: granulocytes
R6: monocytes
rmGM-CSF
MHC II
C
D
86 R7
R8
R9
R7: DC preogenitore
R8: immature DC
R9: mature DC
Bone marrow: Day 0 Day 7-11
 
 
Figure 3. In vitro murine bone marrow derived DC generation. The freshly isolated murine bone marrow contains six populations 
according to CD31 and Ly6C expression. They are CD31–Ly6C– erythrocytes precursors (R1), CD31lowLy6C– lymphoid precursors (R2), 
CD31+Ly6C– early blast cells (R3), CD31lowLy6C+ myeloid blasts (R4), CD31–Ly6C+ granulocytes (R5), and CD31lowLy6Chigh monocytes 
(R6). During culturing with rmGM-CSF, CD31+Ly6C– early blast cells will differentiate into CD31lowLy6C+ myeloid blasts that will further 
differentiate into CD31lowLy6Chigh monocytes. After 7 to 11 days culture with rmGM-CSF, bone marrow precursors will differentiate from 
MHC class II–CD86– progenitors (R7) into MHC class II+ CD86+ immature DC (R8) and further on into MHC class IIhigh CD86high mature DC 
(R9). 
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subpopulations or precursors directly from peripheral blood 
or tissues, due to the small sample size (with maybe the skin 
as an exception). Therefore, DC are mostly generated from 
bone marrow precursors. Bone marrow contains various stem 
cells that can be used in vitro to generate B cells, 
polymorphonuclear neutrophiles, macrophages and DC by 
using different cytokines and growth factors. As in the human 
situation, GM-CSF is essential for the generation of DC from 
bone marrow precursors, whereas IL-4 can be omitted. 
The standard protocol for generating large quantities of 
highly pure dendritic cells from whole bone marrow 
precursors has been described by Lutz et al. in 1999 (31). 
Thereby fresh whole bone marrow cells are cultured with 20 
ng/ml rmGM-CSF for six days with refreshment of the whole 
medium at day 3 and supplementation with another volume 
of new medium at day 5. At day 6 an activation stimulus 
(LPS or IFN-γ) is added for one day. The differentiation and 
maturation state of cultured DC can be followed by their 
MHC class II and CD86 expression: MHCII-CD86- 
precursors develop into MHC IImidCD86mid immature DC 
(iDC). When activated, those iDC mature further on into 
MHC IIhighCD86high mature DC (mDCs) (Figure 3). Alter- 
natively, DC precursors can be isolated from bone marrow 
and subsequently cultured. Bone marrow DC precursors have 
been identified to show different expression levels of CD31 
and Ly6C (Figure 3). CD31highLy6C- early blast cells develop 
into CD31+Ly6C+ myeloid blasts that further develop into 
CD31-Ly6Chigh bone marrow monocytes (32). All of these 
three subsets can be cultured to generate DC, earlier stage 
cells need more time to do so than later stage cells, on the 
other hand they show a higher proliferation. During 
experiments, it is recommended to leave as many factors 
unchanged as possible. One factor that may influence the 
outcome of DC cultures is the age of the bone marrow donor 
mice. To check if it is feasible to freeze bone marrow cells or 
immature DC to increase experiment reliability, an 
experiment was peroformed to compared the yield and 
phenotype of mature DC that have either been obtained (i) by 
culturing fresh bone marrow cells for five days and 
stimulating them for one day, (ii) by culturing frozen bone 
marrow cells for five days and stimulating them for one day, 
or (iii) by stimulating frozen five day immature DC that have 
been isolated over their CD86low expression for one day. No 
differences were found concerning phenotype (CD86, CD80, 
MHC II, CD11c, CD40 and F4/80 expression) and cytokine 
production (IL-10, IL-12p70, and TNF-α) before and after 
stimulation  (not published), but a remarkable difference was 
found in cells yield in the third method where most of the 
immature DC died during the freezing and thawing process, 
the DC yield from fresh and frozen bone marrow were 
comparable. Similar findings have been published before 
(33). Therefore freezing stocks of bone marrow precursors 
from mice that have the same age is a feasible step in 
enhancing reliability of DC cultures. 
Murine plasmacytoid DC precursors can be generated 
similarly to human cells by culturing bone marrow cells with 
Flt3-ligand, which resulted in the generation of 40% pure 
CD11c+CD11b-B220+Gr-1+ plasmacytoid DC precursors. By 
contrast, GM-CSF or TNF-α, which promote the generation 
of CD11c+CD11b+B220- myeloid DC, blocked completely 
the development of plasmacytoid DC precursors (34). These 
results suggest again that the two lineages - myeloid DC and 
plasmacytoid DC precursors - are less related. 
 
Conclusion 
 
Progress in understanding the molecular regulation of DC 
development from hematopoietic stem cells has led to the 
development of in vitro culture systems for the generation of 
large numbers of myeloid DCs from CD34+ hematopoetic 
stem cells with GM-CSF and TNF-α or peripheral blood 
monocytes with GM-CSF and IL-4. Also in the mouse, the 
bone marrow–derived DC can now be generated in a regular 
culture method. The ready culture systems not only permit 
detailed studies of DC biology, but also hold promises for 
DC to become widespread used in medical practice such as 
immunotherapy in cancer and autoimmune diseases. 
Decades after discovering DC, the DC founding father 
Steinman RM once said, "The field is only just beginning." 
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